Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
Search content at Mayo Clinic
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
Pharmacoeconomics of Alzheimer's disease
Jacquelyn Dinusson
,
David Knopman
Neurology
Research output
:
Contribution to journal
›
Review article
›
peer-review
2
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Pharmacoeconomics of Alzheimer's disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Alzheimer's Disease
100%
Pharmacoeconomics
100%
Anti-Alzheimer Drugs
75%
Economic Benefits
62%
Alzheimer's Disease Treatment
37%
Acetylcholinesterase Inhibitors (AChEI)
37%
Dementia
25%
Economic Cost
25%
Informal Care
25%
Economic Modeling
25%
Informal Costs
25%
United States
12%
Most Common Form
12%
Public Health Risk
12%
Health Care Costs
12%
Illness
12%
Advancing Age
12%
Drug Effects
12%
Pharmacological Intervention
12%
Drug Class
12%
Caregiving
12%
Rising Incidence
12%
Dementia with
12%
Clinical Effect
12%
Nursing Home Placement
12%
Order of Magnitude
12%
Medical Services
12%
Cost Savings
12%
Family Caregivers
12%
Treatment Costs
12%
Economic Impact
12%
All Clinical Trials
12%
Potential Gains
12%
Pharmacological Treatment
12%
Economic Model
12%
Long-term Care
12%
Dementia Incidence
12%
Major Diseases
12%
Day Care
12%
Increasing Life Expectancy
12%
Formal Care
12%
Lost Opportunity
12%
Respite Care
12%
Current Benefits
12%
Paid Employment
12%
Developing Economics
12%
Aged Patients
12%
Nursing and Health Professions
Alzheimer's Disease
100%
Pharmacoeconomics
100%
Combination Therapy
23%
Cholinesterase Inhibitor
23%
Patient with Alzheimer's Disease
15%
Diseases
15%
Life Expectancy
7%
Drug Therapy
7%
Nursing Home
7%
Cost Control
7%
Long Term Care
7%
Respite Care
7%
Day Care
7%
Health Care
7%
Pharmacology, Toxicology and Pharmaceutical Science
Alzheimer's Disease
100%
Pharmacoeconomics
100%
Combination Therapy
20%
Cholinesterase Inhibitor
20%
Diseases
13%
Clinical Trial
6%
Life Expectancy
6%
Economics, Econometrics and Finance
Economic Costs
100%
Economic Model Construction
100%
Life Cycle
50%
Veterinary Science and Veterinary Medicine
Drug Therapy
100%